AssetMark Inc’s Xenon Pharmaceuticals XENE Stock Holding History

AssetMark Inc’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$630K	Sell	16,952 -2,382	-12%	-$142K	﹤0.01%	1192
2026 Q2	$1.17M	Sell	19,334 -938	-5%	-$52.1K	﹤0.01%	1063
2026 Q1	$1.18M	Sell	20,272 -997	-5%	-$45.9K	﹤0.01%	1012
2025 Q4	$953K	Sell	21,269 -1,297	-6%	-$54.5K	﹤0.01%	1025
2025 Q3	$906K	Buy	22,566 +1,316	+6%	+$46.4K	﹤0.01%	992
2025 Q2	$665K	Buy	21,250 +1,316	+7%	+$42.9K	﹤0.01%	998
2025 Q1	$669K	Sell	19,934 -1,651	-8%	-$62.7K	﹤0.01%	930
2024 Q4	$846K	Buy	21,585 +1,915	+10%	+$79.2K	﹤0.01%	877
2024 Q3	$774K	Buy	19,670 +1,435	+8%	+$57.9K	﹤0.01%	828
2024 Q2	$711K	Buy	18,235 +5,050	+38%	+$202K	﹤0.01%	824
2024 Q1	$568K	Buy	13,185 +3,247	+33%	+$149K	﹤0.01%	812
2023 Q4	$458K	Buy	9,938 +2,835	+40%	+$100K	﹤0.01%	802
2023 Q3	$243K	Buy	7,103 +1,258	+22%	+$47.1K	﹤0.01%	845
2023 Q2	$225K	Buy	+5,845	New	+$232K	﹤0.01%	827

Other funds holding XENE

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

AssetMark Inc's XENE Position: Q3 2026 in Review

AssetMark Inc reduced its Xenon Pharmaceuticals (XENE) stake by 12% in Q3 2026, selling an estimated $142K and leaving 16,952 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

AssetMark Inc first reported a position in XENE in Q2 2023 and has held it in 14 quarters since. The position peaked at $1.18M in Q1 2026. 73 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

AssetMark Inc held 16,952 shares of Xenon Pharmaceuticals worth $630K as of Q3 2026.
AssetMark Inc sold 2,382 Xenon Pharmaceuticals shares in Q3 2026, an estimated $142K.
Xenon Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1192 holding.
AssetMark Inc first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 14 quarters since.
AssetMark Inc's Xenon Pharmaceuticals position peaked at $1.18M in Q1 2026.
73 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.